Session III of Myeloma2018 featured experts Felipe Prosper, PhD, Brian Walker, PhD, and Constantine Mitsiades, MD, PhD, presenting on the role of epigenetics in multiple myeloma (MM) disease progression.
Several topics were discussed, including chromatin abnormalities, translocations, super-enhancers, mechanisms of resistance, and their association with transcriptional deregulation in MM.
University of Navarra Clinic, Navarra, Spain
Felipe Prosper, PhD, from the University of Navarra Clinic, Navarra, Spain, discusses epigenetics underlying myeloma and disease progression.
UAMS Myeloma Institute, Little Rock, AR
Brian Walker, PhD, from the UAMS Myeloma Institute, Little Rock, AR, speaks about the epigenetic basis of structural changes in multiple myeloma.
Dana-Farber Cancer Institute, Boston, MA
Constantine Mitsiades, MD, PhD, of Dana-Farber Cancer Institute, Boston, MA, discusses the defining mechanisms of resistance and novel therapeutic targets through CRISPR-based studies.